Estrella Immunopharma, Inc. (ESLA)
0.39
-0.02
(-4.90%)
USD |
NASDAQ |
Nov 06, 10:19
Estrella Immunopharma Enterprise Value : 17.50M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | 17.50M |
| November 04, 2026 | 18.94M |
| November 03, 2026 | 17.84M |
| November 02, 2026 | 18.20M |
| October 30, 2026 | 27.37M |
| October 29, 2026 | 31.21M |
| October 28, 2026 | 35.21M |
| October 27, 2026 | 39.97M |
| October 26, 2026 | 39.39M |
| October 23, 2026 | 42.24M |
| October 22, 2026 | 31.13M |
| October 21, 2026 | 23.52M |
| October 20, 2026 | 17.07M |
| October 19, 2026 | 16.20M |
| October 16, 2026 | 18.36M |
| October 15, 2026 | 22.89M |
| October 14, 2026 | 13.53M |
| October 13, 2026 | 13.37M |
| October 12, 2026 | 13.99M |
| October 09, 2026 | 17.50M |
| October 08, 2026 | 17.82M |
| October 07, 2026 | 17.90M |
| October 06, 2026 | 18.32M |
| October 05, 2026 | 18.79M |
| October 02, 2026 | 19.99M |
| Date | Value |
|---|---|
| October 01, 2026 | 20.29M |
| September 30, 2026 | 19.94M |
| September 29, 2026 | 19.65M |
| September 28, 2026 | 18.42M |
| September 25, 2026 | 20.55M |
| September 24, 2026 | 20.12M |
| September 23, 2026 | 20.17M |
| September 22, 2026 | 20.72M |
| September 21, 2026 | 21.47M |
| September 18, 2026 | 22.62M |
| September 17, 2026 | 22.49M |
| September 16, 2026 | 27.39M |
| September 15, 2026 | 26.15M |
| September 14, 2026 | 27.20M |
| September 11, 2026 | 28.24M |
| September 10, 2026 | 28.82M |
| September 09, 2026 | 27.31M |
| September 08, 2026 | 27.41M |
| September 04, 2026 | 27.67M |
| September 03, 2026 | 27.44M |
| September 02, 2026 | 29.55M |
| September 01, 2026 | 29.61M |
| August 31, 2026 | 31.05M |
| August 28, 2026 | 30.20M |
| August 27, 2026 | 30.92M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.737B |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| Anika Therapeutics, Inc. | 245.53M |
| Savara, Inc. | 757.02M |
| Vericel Corp. | 2.582B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.306M |
| Total Expenses (Quarterly) | 2.306M |
| EPS Diluted (Quarterly) | -0.0536 |
| Earnings Yield | -65.03% |
| Normalized Earnings Yield | -63.64 |